
Novo Nordisk expects to turn its US growth up a notch, since the company is back to growing on this market after a stagnation and price pressure-riddled 2019.
Novo's total US sales rose 3 percent in local currency to DKK 57.8bn (USD 9.3bn) last year, and it will be even better this year.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app